Catherine MS - Citius Pharmaceuticals Executive Affairs
| CTXR Stock | USD 3.32 0.28 7.78% |
Executive
Catherine MS is Executive Affairs of Citius Pharmaceuticals
| Address | 11 Commerce Drive, Cranford, NJ, United States, 07016 |
| Phone | 908 967 6677 |
| Web | https://citiuspharma.com |
Citius Pharmaceuticals Management Efficiency
The company has return on total asset (ROA) of (0.2474) % which means that it has lost $0.2474 on every $100 spent on assets. This is way below average. Similarly, it shows a return on stockholder's equity (ROE) of (0.4149) %, meaning that it created substantial loss on money invested by shareholders. Citius Pharmaceuticals' management efficiency ratios could be used to measure how well Citius Pharmaceuticals manages its routine affairs as well as how well it operates its assets and liabilities. As of 11/29/2024, Return On Tangible Assets is likely to drop to -0.88. In addition to that, Return On Capital Employed is likely to grow to -0.41. At this time, Citius Pharmaceuticals' Total Assets are relatively stable compared to the past year. As of 11/29/2024, Total Current Assets is likely to grow to about 41.5 M, while Non Currrent Assets Other are likely to drop slightly above 41.6 K.Similar Executives
| Showing other executives | EXECUTIVE Age | ||
| John Stubenrauch | Day One Biopharmaceuticals | N/A | |
| Robert Arbeit | X4 Pharmaceuticals | 76 | |
| RAC Dilon | Immunitybio | 57 | |
| Elizabeth Esq | Ardelyx | 60 | |
| MBA MD | X4 Pharmaceuticals | 62 | |
| Charon Sr | Ardelyx | N/A | |
| Robyn MA | Acumen Pharmaceuticals | N/A | |
| Pamela Danagher | Terns Pharmaceuticals | N/A | |
| Desiree Gendron | Lexicon Pharmaceuticals | N/A | |
| Sarah Singleton | Immunitybio | N/A | |
| Mike Kelliher | Ardelyx | 47 | |
| Caroline Holda | Seres Therapeutics | N/A | |
| Carlo Tanzi | Seres Therapeutics | N/A | |
| Carrie Siragusa | Lexicon Pharmaceuticals | N/A | |
| Pharm MPH | X4 Pharmaceuticals | N/A | |
| Adam Dubow | Day One Biopharmaceuticals | 57 | |
| Scott Harris | Terns Pharmaceuticals | N/A | |
| Mark MBA | X4 Pharmaceuticals | 60 | |
| Kristen Alexander | Lexicon Pharmaceuticals | 56 | |
| MPH MD | Ardelyx | 60 | |
| Samuel Berry | Fortress Biotech | N/A | |
Management Performance
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 |
Citius Pharmaceuticals Leadership Team
Elected by the shareholders, the Citius Pharmaceuticals' board of directors comprises two types of representatives: Citius Pharmaceuticals inside directors who are chosen from within the company, and outside directors, selected externally and held independent of Citius. The board's role is to monitor Citius Pharmaceuticals' management team and ensure that shareholders' interests are well served. Citius Pharmaceuticals' inside directors are responsible for reviewing and approving budgets prepared by upper management to implement core corporate initiatives and projects. On the other hand, Citius Pharmaceuticals' outside directors are responsible for providing unbiased perspectives on the board's policies.
| Myron MD, Executive Officer | ||
| Dhananjay Wadekar, Senior Strategy | ||
| Leonard Mazur, Chairman of the Board, Secretary | ||
| Catherine MS, Executive Affairs | ||
| Jaime Bartushak, CFO, Principal Financial Officer | ||
| Nikolas Burlew, Executive Assurance | ||
| Ilanit Allen, Vice Communications | ||
| Myron Holubiak, President CEO, Director | ||
| Kelly Creighton, Manufacturing Chemistry | ||
| Gary Talarico, Executive Operations | ||
| Alan Lader, Senior Assurance |
Citius Stock Performance Indicators
The ability to make a profit is the ultimate goal of any investor. But to identify the right stock is not an easy task. Is Citius Pharmaceuticals a good investment? Although profit is still the single most important financial element of any organization, multiple performance indicators can help investors identify the equity that they will appreciate over time.
| Return On Equity | -0.41 | ||||
| Return On Asset | -0.25 | ||||
| Current Valuation | 10.23 M | ||||
| Shares Outstanding | 180.72 M | ||||
| Shares Owned By Insiders | 6.80 % | ||||
| Shares Owned By Institutions | 17.02 % | ||||
| Number Of Shares Shorted | 13.45 M | ||||
| Price To Earning | (1.34) X | ||||
| Price To Book | 0.32 X | ||||
| EBITDA | (36.73 M) |
Pair Trading with Citius Pharmaceuticals
One of the main advantages of trading using pair correlations is that every trade hedges away some risk. Because there are two separate transactions required, even if Citius Pharmaceuticals position performs unexpectedly, the other equity can make up some of the losses. Pair trading also minimizes risk from directional movements in the market. For example, if an entire industry or sector drops because of unexpected headlines, the short position in Citius Pharmaceuticals will appreciate offsetting losses from the drop in the long position's value.Moving together with Citius Stock
| 0.71 | HLN | Haleon plc | PairCorr |
| 0.71 | JNJ | Johnson Johnson Fiscal Year End 28th of January 2025 | PairCorr |
| 0.74 | PFE | Pfizer Inc Aggressive Push | PairCorr |
| 0.68 | ANRO | Alto Neuroscience, | PairCorr |
Moving against Citius Stock
| 0.82 | AXP | American Express Fiscal Year End 24th of January 2025 | PairCorr |
| 0.75 | TRV | The Travelers Companies Fiscal Year End 17th of January 2025 | PairCorr |
| 0.69 | FNMFO | Federal National Mortgage Upward Rally | PairCorr |
| 0.67 | KB | KB Financial Group | PairCorr |
| 0.62 | ITCL | Banco Ita Chile | PairCorr |
The ability to find closely correlated positions to Citius Pharmaceuticals could be a great tool in your tax-loss harvesting strategies, allowing investors a quick way to find a similar-enough asset to replace Citius Pharmaceuticals when you sell it. If you don't do this, your portfolio allocation will be skewed against your target asset allocation. So, investors can't just sell and buy back Citius Pharmaceuticals - that would be a violation of the tax code under the "wash sale" rule, and this is why you need to find a similar enough asset and use the proceeds from selling Citius Pharmaceuticals to buy it.
The correlation of Citius Pharmaceuticals is a statistical measure of how it moves in relation to other instruments. This measure is expressed in what is known as the correlation coefficient, which ranges between -1 and +1. A perfect positive correlation (i.e., a correlation coefficient of +1) implies that as Citius Pharmaceuticals moves, either up or down, the other security will move in the same direction. Alternatively, perfect negative correlation means that if Citius Pharmaceuticals moves in either direction, the perfectly negatively correlated security will move in the opposite direction. If the correlation is 0, the equities are not correlated; they are entirely random. A correlation greater than 0.8 is generally described as strong, whereas a correlation less than 0.5 is generally considered weak.
Correlation analysis and pair trading evaluation for Citius Pharmaceuticals can also be used as hedging techniques within a particular sector or industry or even over random equities to generate a better risk-adjusted return on your portfolios.Additional Tools for Citius Stock Analysis
When running Citius Pharmaceuticals' price analysis, check to measure Citius Pharmaceuticals' market volatility, profitability, liquidity, solvency, efficiency, growth potential, financial leverage, and other vital indicators. We have many different tools that can be utilized to determine how healthy Citius Pharmaceuticals is operating at the current time. Most of Citius Pharmaceuticals' value examination focuses on studying past and present price action to predict the probability of Citius Pharmaceuticals' future price movements. You can analyze the entity against its peers and the financial market as a whole to determine factors that move Citius Pharmaceuticals' price. Additionally, you may evaluate how the addition of Citius Pharmaceuticals to your portfolios can decrease your overall portfolio volatility.